Frank A. Damelio - 26 Feb 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
Susan E. Grant, by power of atty., for Frank A. D'Amelio
Issuer symbol
PFE
Transactions as of
26 Feb 2022
Net transactions value
-$1,402,647
Form type
4
Filing time
01 Mar 2022, 16:55:21 UTC
Previous filing
25 Feb 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $3,255,296 +127,160 +24% $25.60 649,918 26 Feb 2022 Direct F1
transaction PFE Common Stock Tax liability $1,651,446 -34,607 -5.3% $47.72 615,311 26 Feb 2022 Direct F2, F3
transaction PFE Common Stock Tax liability $3,006,497 -59,370 -9.6% $50.64 555,941 26 Feb 2022 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -127,160 -100% $0.000000* 0 26 Feb 2022 Common Stock 127,160 $25.60 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 Price is the closing price of Pfizer common stock on February 25, 2022.
F4 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.